Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

147
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
147
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

88
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
88
Dosage Interval and Administration Route: Determination Methods01:19

Dosage Interval and Administration Route: Determination Methods

129
A medication’s effectiveness largely depends on its appropriate dosage and the route of administration. Dosage ensures that a sufficient drug concentration is maintained in the bloodstream to elicit the desired therapeutic effect without causing toxicity. The route of administration affects the drug's bioavailability, rate of absorption, and onset of action, which are crucial for achieving optimal therapeutic outcomes. Drug dosage calculations are critical to tailoring therapy to...
129
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

128
Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
128
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

177
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
177
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

128
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
128

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact on daptomycin resistance using combination of daptomycin plus ceftaroline in daptomycin-susceptible and -resistant <i>Staphylococcus aureus</i>.

FEMS microbes·2026
Same author

Elevated urinary glycosaminoglycans in <i>Staphylococcus aureus</i> bacteraemia with endovascular source.

Journal of medical microbiology·2026
Same author

Unlocking the secret to <i>Staphylococcus aureus</i> survival in serum.

mSystems·2026
Same author

A national survey of the infectious diseases and antimicrobial stewardship pharmacist workforce in the United States: work settings, characteristics, employment activities, resources and needs.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026
Same author

Electrophysiological effects of psilocybin co-administered with midazolam.

Translational psychiatry·2026
Same author

Telehealth: The Way for Efficient, Comprehensive, and Equitable Antimicrobial Stewardship in the US Healthcare System.

Open forum infectious diseases·2025

Related Experiment Video

Updated: Dec 17, 2025

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

1.7K

A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis.

Warren E Rose1, Paul R Hutson2

  • 1School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA. warren.rose@wisc.edu.

Drugs - Real World Outcomes
|June 27, 2020
PubMed
Summary

A two-dose oritavancin regimen (1200 mg followed by 800 mg one week later) maintains therapeutic concentrations for longer than a single dose, offering a potential option for prolonged treatment of multidrug-resistant Gram-positive infections.

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.3K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.3K

Related Experiment Videos

Last Updated: Dec 17, 2025

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

1.7K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.3K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.3K

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Infectious Diseases
  • Antimicrobial Therapy

Background:

  • Limited treatment options exist for complicated, multidrug-resistant Gram-positive infections requiring prolonged therapy.
  • Oritavancin is approved as a single 1200 mg dose for skin infections, but supplemental doses have been reported.

Purpose of the Study:

  • To determine population pharmacokinetic estimates for a 1200 mg single oritavancin dose compared to a two-dose regimen (1200 mg followed by 800 mg one week later).

Main Methods:

  • Simulated administration of a 1200 mg oritavancin dose over 3 hours, followed 7 days later by a simulated 800 mg dose over 3 hours.
  • Population pharmacokinetic estimation was performed.

Main Results:

  • The two-dose oritavancin regimen demonstrated predictable linear pharmacokinetics and achieved therapeutic concentrations.
  • Total and free oritavancin concentrations remained above the susceptibility breakpoint for 8 weeks and 4.6 weeks, respectively, significantly longer than the single-dose regimen.
  • The two-dose regimen resulted in a greater area under the drug concentration-time curve (AUC) above the susceptibility breakpoint and maintained a high AUC:MIC ratio for specific MIC values.

Conclusions:

  • The 1200 mg followed by 800 mg regimen provides extended therapeutic concentrations.
  • This dosing strategy warrants further investigation for prolonged oritavancin treatment in indicated cases, supported by existing observational data.